Vanillin oxime inhibits lung cancer cell proliferation and activates apoptosis through JNK/ERK-CHOP pathway

Jie Shen¹ and Zhixiang Su²*

¹Department of Respiratory, Yan'an People's Hospital, Yan'an, Shaanxi 716000, ²Department of Medical Oncology Hospital Unit 3, Shaanxi Provincial Cancer Hospital, Xian 710061, China

ABSTRACT Lung cancer despite advancement in the medical field continues to be a major threat to human lives and accounts for a high proportion of fatalities caused by cancers globally. The current study investigated vanillin oxime, a derivative of vanillin, against lung cancer cells for development of treatment and explored the mechanism. Cell viability changes by vanillin oxime were measured using MTT assay. Vanillin oxime-mediated apoptosis was detected in A549 and NCI-H2170 cells at 48 h of exposure by flow cytometry. The CEBP homologous protein (CHOP) and death receptor 5 (DR5) levels were analysed by RT-PCR and protein levels by Western blotting. Vanillin oxime in concentration-dependent way suppressed A549 and NCI-H2170 cell viabilities. On exposure to 12.5 and 15 μM concentrations of vanillin oxime elevated Bax, caspase-3, and -9 levels in A549 and NCI-H2170 cells were observed. Vanillin oxime exposure suppressed levels of Bcl-2, survivin, Bcl-xL, cFLIP, and IAPs proteins in A549 and NCI-H2170 cells. It stimulated significant elevation in DR4 and DR5 levels in A549 and NCI-H2170 cells. In A549 and NCI-H2170 cells vanillin oxime exposure caused significant (p < 0.05) enhancement in CHOP and DR5 mRNA expression. Vanillin oxime exposure of A549 and NCI-H2170 cells led to significant (p < 0.05) enhancement in levels of phosphorylated extracellular-signal-regulated kinase and c-Jun N-terminal kinase. Thus, vanillin oxime inhibits pulmonary cell proliferation via induction of apoptosis through tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated pathway. Therefore, vanillin oxime may be studied further to develop a treatment for lung cancer.

INTRODUCTION

Lung cancer despite advancement in the medical field continues to be a major threat to human lives and accounts for a high proportion of fatalities caused by cancers globally [1]. Small cell and non-small cell lung cancers (NSCLC) respectively contribute 15% and 85% of the total pulmonary cancer patients diagnosed worldwide [2]. The rate of 5-year survival for patients with NSCLC is only 15% even after huge advancement in chemo- and radiation therapies for [3]. Development of more efficient treatment strategies for pulmonary cancer are thereby immediately required to improve survival of patients.

Most crucial way to arrest tumor development and inhibit carcinoma progression is via induction of apoptosis. Majority of the researchers are searching for molecules which activate pathways involved in apoptosis and therefore accelerate death of cells. Selective carcinoma cell death is activated by tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) which is an apoptosis inducing ligand related with tumor necrosis factor [4,5]. In activating death TRAIL interacts with receptors namely, DR4 and DR5 present in membranes via its ligands [6]. Moreover, TRAIL also influences decoy receptors including DcR-1 and DcR-2 in

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © Korean J Physiol Pharmacol, plISSN 1226-4512, eISSN 2093-3827
addition to osteoprotegerin which are devoid of transmembrane domain [7]. On interacting with DR4 and DR5, TRAIL causes induction of death signal via activation of both initiator as well as effector caspases leading to apoptosis [8,9]. Elevated decoy receptor levels and suppressed DRs are associated with cell resistance to TRAIL mediated apoptosis [9,10]. Besides, excessive FLICE-like inhibitory proteins (cFLIPs) also lead to resistance to TRAIL induced death [11].

Four-hydroxy-3-methoxybenzaldehyde (Fig. 1), commonly called as vanillin is present in the seeds of Vanilla planifolia plant. The compound initially used as flavoring agent was latter reported to possess anti-microbial, anti-mutagenic and anti-inflammatory properties in rodent and human models [12-15]. Vanillin targets nuclear factor-κB expression and activity of MMP’s to arrest migration and invasiveness of liver carcinoma cells [16]. In pulmonary cancer cells angiogenesis and development of lamellipodia is inhibited by vanillin by targeting PI3K activation [17-19]. Signals to induce apoptosis in breast and cervical carcinoma cells are initiated by vanillin to inhibit tumor growth [17-19]. The current study investigated vanillin oxime, a derivative of vanillin against lung cancer cells for development of treatment and explored mechanism.

**METHODS**

**Drugs and reagents**

Vanillin oxime (Cas number S539570; purity 99%) was supplied by Merck Chemicals. Dimethyl sulfoxide (DMSO) and many other chemicals were provided by the Sigma-Aldrich (St Louis, MO, USA).

**Cell lines**

Lung cancer cell lines (A549 and NCI-H2170) and normal epithelial cells (BEAS-2B) were supplied by the ATCC, Rockville, MD, USA and maintained in RPMI-1640 medium provided with 10% FBS at 37°C in incubator with 5% CO₂ atmosphere. Supplementation of medium was made with penicillin (100 units/ml) and streptomycin (100 μg/ml).

**Cell viability assay**

The A549, BEAS-2B and NCI-H2170 cell viability changes by vanillin oxime were measured using 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay. Cells maintained for 24 h in RPMI-1640 medium at 2 × 10⁶ cells/well density in 96-well plates were exposed for 48 h to 5, 7.5, 10, 12.5, 15, 17.5, and 20 μM concentrations of vanillin oxime. Medium was changed and then MTT (20 μl; 0.5 mg/ml) solution was poured in each well to incubate cells for 4 h. Afterwards, DMSO (120 μl) was added to the wells and optical density was recorded by Multiskan Spectrometer (Vantaa, Finland) at 574 nm.

**Analysis of apoptosis**

Vanillin oxime-mediated apoptosis was detected in A549 and NCI-H2170 cells at 48 h of exposure by flow cytometry. Exposure of cells to 12.5 and 15 μM concentrations of vanillin oxime was followed by treatment with annexin V-FITC reagent (5 μl) for 35 min at room temperature. Apoptotic cell fraction was analysed using FACs Calibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

**Western blotting**

The A549 and NCI-H2170 cells were exposed to 12.5 and 15 μM concentrations of vanillin oxime for 48 h. After exposure, incubation was carried with ice-cold (0.5 ml) lystate buffer (consisting of NaCl [5 M], NaVO₄ [0.2 M], Nonidet P-40 [10%], EGTA [0.1 M], EDTA [0.5 M], PhCH₂SO₂F [0.1 M], NaF [1 M], HEPES [1 M] aprotinin [2 μg/ml] and leupeptin [2 μg/ml]) for 45 min. After centrifugation at 12,000 ×g at 4°C protein level in supernatant separated from the lysates was estimated by Bio-Rad assay (Bio-

![Fig. 1. Effect of vanillin oxime on A549 and NCI-H2170 cells.](image)
Rad, Hercules, CA, USA). Fractionation of 60 μg protein samples on SDS-PAGE was followed by transfer to PVDF membranes (Millipore, Bedford, MA, USA). Probing of proteins was carried out by over-night membrane incubation at 4°C with primary antibodies. Washing membranes with TBST was followed by incubating the blots for 1 h with anti-rabbit secondary antibodies conjugated to horseradish peroxidase. Detection as well as analysis of the bands was carried out using the ECL western blot analysing system (Biotech Inc., USA). The primary antibodies used were against JNK, p-JNK, caspase-3, -8, -9, CHOP, Bcl-xL, ERK1/2, p-ERK1/2, DR4, DR5, survivin, Bax, cFLIP, xIAP (Cell Signaling Technology, Danvers, MA, USA).

Determination of DR4 and DR5 levels

Mouse anti-human antibodies against DR4 as well as DR5 which are conjugated to the phycoerythrin (Minneapolis, MN, USA) were used for analysis death receptors in A549 and NCI-H2170 cells. The cells at 2 x 10^6 cells/well distribution were exposed to 12.5 and 15 μM concentrations of vanillin oxime for 48 h. Then incubation with antibodies was done for 50 min at 4°C to analyse receptor expression using flow cytometry.

RT-PCR analysis

To determine levels of CHOP and DR5 mRNA in A549 and NCI-H2170 cells after exposure to 12.5 and 15 μM vanillin oxime RT-PCR was used. From A549 and NCI-H2170 cells total RNA was isolated at 48 h of vanillin oxime exposure by TRIZol reagent (Invitrogen, Carlsbad, CA, USA). Primer sequences used for PCR were as follows: CHOP, forward 5’CAACTGCAGATGGCAGCTGA-3’ and reverse 5’CTGATGCTCCCAATTGTCCAT-3’; DR5, forward 5’-AGACACCTTTGCTCGTTGTC-3’ and reverse 5’-GACACATTCGATGTCACTC-3’; and GAPDH, forward 5’-GTCTTCCACCACTCGAG3’ and reverse 5’-CCACCTGGTGTGCTAGAC3’.

siRNA transfection

Effect of silencing CHOP and DR5 on A549 and NCI-H2170 cells followed by exposure to vanillin oxime was also studied. Transfection of 30 nM siRNA (oligonucleotides) to A549 and NCI-H2170 cells was performed using lipofectamine 2000 (Invitrogen) as per the manual procedure [20]. Then cells were exposed for 48 h to 12.5 and 15 μM vanillin oxime followed by western blotting to detect changes in CHOP and DR5 expression.

Statistical analysis

The data expressed are mean ± standard deviation of the measurements made in triplicates. To analyse data statistically SPSS software (IBM Corp.) was used. Differences between groups were statistically determined by one-way ANOVA and Duncan’s test (DMRT). The values at p < 0.05 were taken to be statistically significant.

RESULTS

Vanillin oxime is cytotoxic

A549 and NCI-H2170 cells were exposed to vanillin oxime at 5, 7.5, 10, 12.5, 15, 17.5, and 20 μM concentrations (Fig. 1). Vanillin oxime in concentration dependent way suppressed A549 and NCI-H2170 cell viabilities at 48 h. At 5 and 20 μM concentrations vanillin oxime exposure reduced A549 cell viability to 87 and 21%, respectively. Viabilities of NCI-H2170 cells were suppressed to 90 and 24%, respectively on exposure to 5 and 20 μM concentrations vanillin oxime. As viabilities of A549 and NCI-H2170 cells were reduced to intermediate level at 12.5 and 20 μM therefore only these two concentrations were chosen for further studies.

Vanillin oxime is apoptotic agent

Vanillin oxime mediated apoptosis in A549 and NCI-H2170 cells at 48 h was detected by Annexin V staining (Fig. 2). Exposure to 12.5 and 15 μM concentrations of vanillin oxime increased A549 and NCI-H2170 cell apoptosis significantly (p < 0.05). Vanillin oxime at 12.5 and 15 μM led to apoptosis in 48.23 and 63.91% A549 cells, respectively. In NCI-H2170 cells apoptosis reached to 45.14 and 59.37%, respectively on exposure to vanillin oxime at 12.5 and 15 μM concentrations.

Vanillin oxime promoted pro-apoptotic proteins

In vanillin oxime exposed A549 and NCI-H2170 cells pro-apoptotic protein levels were assayed at 48 h by western blotting (Fig. 3). On exposure to 12.5 and 15 μM concentrations of vanillin oxime elevated cleaved caspase-3 and -9 levels in A549 and NCI-H2170 cells were observed. In vanillin oxime (12.5 and 15 μM) exposed A549 and NCI-H2170 cells Bax level was also higher relative to untreated cells.

Vanillin oxime targeted survival protein expression

Vanillin oxime exposure at 12.5 and 15 μM concentrations suppressed levels of Bcl-2, survivin, Bcl-xL, cFLIP and IAPs proteins in A549 and NCI-H2170 cells (Fig. 4). In control A549 and NCI-H2170 cells Bcl-2, survivin, Bcl-xL, cFLIP and IAPs protein levels were observed to be markedly higher compared to vanillin oxime treated cells. In A549 and NCI-H2170 cells protein expression was determined at 48 h using Western blotting assay.
Vanillin oxime up-regulated DR4 and DR5

In A549 and NCI-H2170 cells exposure to 12.5 and 15 μM concentrations of vanillin oxime was followed by DR4 and DR5 expression assessment (Fig. 5). Vanillin oxime exposure stimulated significant elevation in DR4 and DR5 levels in A549 and NCI-H2170 cells at 48 h. Promotion in DR4 and DR5 levels was higher on treatment with 15 μM vanillin oxime compared to 12.5 μM concentration.

Vanillin oxime promoted CHOP expression

In A549 and NCI-H2170 cells vanillin oxime exposure at 12.5 and 15 μM doses caused significant (p < 0.05) enhancement in CHOP and DR5 expression (Fig. 6). Vanillin oxime exposure at 12.5 and 15 μM doses also elevated CHOP protein level in A549 cells.
Vanillin oxime inhibits lung cancer cell proliferation

Vanillin oxime exposure of A549 and NCI-H2170 cells at 12.5 and 15 μM doses led to significant (p < 0.05) enhancement in levels of phosphorylated ERK and JNK (Fig. 8). Enhancement in p-ERK and p-JNK levels by vanillin oxime was higher at 15 μM doses relative to 12.5 μM concentration. Treatment of A549 and NCI-H2170 cells with JNK inhibitor (SP600125) as well as ERK1/2 inhibitor (PD98059) led to prominent reduction in vanillin oxime induced DR5 and DR4 levels (Fig. 9).

DISCUSSION

Vanillin was shown to possess anticarcinogenic activity in rats and as antimutagen in several in vitro models [13,21]. It potentiates cytotoxicity of many DNA-damaging agents such as cisplatin [22] and mitomycin C [23]. Moreover, vanillin demonstrated anti-metastatic activity for 4T1-mouse mammary carcinoma and inhibited invasiveness and migration of tumor cells in vitro [18]. Resistance to death induced by TRAIL is linked with the higher survival protein levels including, cFLIP, Bcl-2, survivin...
and Bcl-xL in carcinoma cells [24,25]. Targeting expression of these proteins which are associated with resistance to death induced by TRAIL has prominent potential in cancer treatment strategies. In the present study vanillin oxime suppressed A549 and NCI-H2170 cell viabilities in concentration dependent way. Thus, vanillin oxime was found to be cytotoxic agent for A549 and NCI-H2170 cells from initial MTT studies. Further studies demonstrated that exposure to vanillin oxime increased A549 and NCI-H2170 cell apoptosis significantly (p < 0.05). In vanillin oxime exposed A549 and NCI-H2170 cells caspase-3 and -9 levels were enhanced excessively relative to untreated cells. Moreover, vanillin oxime exposure of A549 and NCI-H2170 cells also raised Bax level significantly. Vanillin oxime exposure suppressed levels of cFLIP, Bcl-2, survivin and Bcl-xL proteins in dose-based way in A549 and NCI-H2170 cells. Therefore, vanillin oxime exhibited toxicity for A549 and NCI-H2170 cells by inducing apoptosis through targeting anti-apoptotic proteins.

Plant derived compounds promote death of carcinoma cells via...
Vanillin oxime inhibits lung cancer cell proliferation

TRAIL-mediated pathway through targeting survival proteins and elevation of caspases [26,27]. Resistance of cancers to TRAIL is related with dysregulated DR4 and DR5 levels and thereby up-regulation induces cell death [28,29]. In the present study vanillin oxime exposure stimulated significant elevation in DR4 and DR5 levels in A549 and NCI-H2170 cells. Moreover, elevation of DR4 and DR5 levels was higher on exposure to higher doses of vanillin oxime compared to lower concentrations.

The DR5 level is regulated by a transcriptional factor known as C/EBP homologous protein (CHOP) in various cells [30]. The expression of DR5 is promoted by CHOP on binding to the promoter region of DR5 [30]. The present study found that A549 and NCI-H2170 cells expressed significantly (p < 0.05) enhanced CHOP and DR5 mRNA expression on vanillin oxime exposure. Vanillin oxime exposure also elevated CHOP protein level in A549 and NCI-H2170 cells. Moreover, CHOP and DR5 expression was significantly lowered in vanillin oxime exposed A549 and NCI-H2170 cells on CHOP-siRNA transfection.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

505-515.


